A Study of DB-1310 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

Trial Details

NCT ID
NCT05785741
Phase
PHASE1 / PHASE2
Sponsor
DualityBio Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • DB-1310
  • Trastuzumab
  • Osimertinib
  • capecitabine
Locations (sample)
  • Sacramento, California, United States|38.58157,-121.4944
  • Santa Monica, California, United States|34.01949,-118.49138
  • Coral Gables, Florida, United States|25.72149,-80.26838
  • Margate, Florida, United States|26.24453,-80.20644
  • Orlando, Florida, United States|28.53834,-81.37924

Key Eligibility Criteria

  • Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed…
  • Have relapsed or progressed on or after standard systemic treatments, or intolerable with standard treatment, or for which no standard treatment is…
  • At least one measurable lesion as assessed by the investigator according to response evaluation criteria in solid tumors (RECIST) version 1.1 crite…
  • Has a life expectancy of ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →